List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Celgene Corp
Chong Kun Dang Pharmaceutical Corp
Curis Inc
HitGen LTD
Kancera AB
Karus Therapeutics Ltd
Medivir AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
OnKure Inc
Quimatryx SL
Shuttle Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
citarinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IKH-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-2507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPT-0B291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexturastat A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-259 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
Sep 27, 2017: Clinical trial reveals genetic fault that reduces the effectiveness of leukaemia treatment
Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma
Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by Kancera AB, H1 2018
Pipeline by Karus Therapeutics Ltd, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by OnKure Inc, H1 2018
Pipeline by Quimatryx SL, H1 2018
Pipeline by Shuttle Pharmaceuticals LLC, H1 2018
Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Companies Mentioned
• AlfaSigma SpA
• Celgene Corp
• Chong Kun Dang Pharmaceutical Corp
• Curis Inc
• HitGen LTD
• Kancera AB
• Karus Therapeutics Ltd
• Medivir AB
• Merck & Co Inc
• Millennium Pharmaceuticals Inc
• OnKure Inc
• Quimatryx SL
• Shuttle Pharmaceuticals LLC
• SK Biopharmaceuticals Co Ltd